Similar articles

• Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis.

  Blauvelt A. Blauvelt A. JAMA Dermatol. 2024 Mar 1;160(3):370. doi: 10.1001/jamadermatol.2023.6198. JAMA Dermatol. 2024. PMID: 38353963 No abstract available.
• Safety of dupilumab in patients with atopic dermatitis: expert opinion.

  Francuzik W, Alexiou A, Worm M. Francuzik W, et al. Expert Opin Drug Saf. 2021 Sep;20(9):997-1004. doi: 10.1080/14740338.2021.1939673. Epub 2021 Jun 19. Expert Opin Drug Saf. 2021. PMID: 34114910 Review.
• Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series.

  Mareschal A, Puzenat E, Aubin F. Mareschal A, et al. Acta Derm Venereol. 2020 Jan 7;100(1):adv00014. doi: 10.2340/00015555-3368. Acta Derm Venereol. 2020. PMID: 31709451 Free PMC article. No abstract available.
• Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients.

  Ordóñez-Rubiano MF, Campo I, Casas M. Ordóñez-Rubiano MF, et al. Dermatol Ther. 2020 Nov;33(6):e14172. doi: 10.1111/dth.14172. Epub 2020 Sep 5. Dermatol Ther. 2020. PMID: 32779378 Free PMC article. No abstract available.
• Les traitements systémiques de la dermatite atopique: Systemic treatments of atopic dermatitis.

  Lacour JP. Lacour JP. Ann Dermatol Venereol. 2019 Dec;146(12S3):12S76-12S84. doi: 10.1016/S0151-9638(20)30017-X. Ann Dermatol Venereol. 2019. PMID: 31997736 Review. French.